Align Files Patent Lawsuit Against Chinese Rival Stock Ranks 460th in Market Activity as Dental Tech Competition Intensifies

Align Technology, Inc. (ALGN) closed August 20 with a 0.13% decline, trading at $143.22 with a daily volume of $220 million, ranking 460th in market activity. The stock’s muted performance coincided with a significant legal development as the company initiated patent infringement litigation against Angelalign Technology, a Chinese competitor. Align alleges that Angelalign’s products infringe on its intellectual property related to clear aligners and digital orthodontic solutions, a move that could intensify competition in the dental tech sector.

The lawsuit underscores Align’s strategic focus on protecting its market position in the clear aligner industry, where it holds a dominant share through brands like Invisalign. Analysts note that such legal actions often signal a company’s confidence in its proprietary technology and may influence investor sentiment in the short term. However, the broader sector remains competitive, with rivals increasingly adopting AI-driven tools and expanding product portfolios to capture market share. Align’s recent earnings report, which showed a 1.6% sequential revenue decline, highlights the challenges of sustaining growth amid rising costs and regulatory scrutiny.

A backtest of a high-volume trading strategy revealed mixed results for short-term traders. From 2022 to 2025, buying the top 500 stocks by daily volume and holding for one day yielded a 31.52% total return over 365 days, with a 0.98% average daily gain. The strategy peaked in June 2023 with 7.02% returns but faced a -4.20% loss in September 2022, reflecting market volatility. While the approach captured momentum in sectors like dental tech, its effectiveness remains tied to liquidity and market conditions, making it a high-risk proposition for traders.